{"id":18065,"date":"2021-01-10T16:18:30","date_gmt":"2021-01-10T14:18:30","guid":{"rendered":"https:\/\/vilkaviskiovsb.lt\/?p=18065"},"modified":"2021-01-10T16:18:30","modified_gmt":"2021-01-10T14:18:30","slug":"sam-informuoja-gydymo-istaigos-gales-naudoti-sesta-biontech-ir-pfizer-vakcinos-doze","status":"publish","type":"post","link":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/2021\/01\/10\/sam-informuoja-gydymo-istaigos-gales-naudoti-sesta-biontech-ir-pfizer-vakcinos-doze\/","title":{"rendered":"SAM informuoja: gydymo \u012fstaigos gal\u0117s naudoti \u0161e\u0161t\u0105 \u201eBioNTech\u201c ir \u201ePfizer\u201c vakcinos doz\u0119"},"content":{"rendered":"<p><strong>Europos vaist\u0173 agent\u016bra (EVA) penktadien\u012f pritar\u0117 si\u016blymui d\u0117l \u0161e\u0161tos \u201eBioNTech\u201c ir \u201ePfizer\u201c vakcinos \u201eComirnaty\u201c doz\u0117s panaudojimo. Nuo \u0161iol Lietuvos asmens sveikatos prie\u017ei\u016bros \u012fstaigos (ASP\u012e), atsakingos u\u017e gyventoj\u0173 skiepijim\u0105 nuo COVID-19 ligos, gal\u0117s naudoti \u0161e\u0161t\u0105j\u0105 vakcinos doz\u0119.<\/strong><\/p>\n<p>EVA penktadien\u012f rekomendavo Europos Komisijai papildyti Covid-19 vakcinos \u201eComirnaty\u201c charakteristik\u0173 santrauk\u0105, kad paruo\u0161toje vakcinoje gali b\u016bti 6 doz\u0117s. Nurodoma papildoma s\u0105lyga, kad b\u016bt\u0173 naudojami tam tikras specifikacijas atitinkantys \u0161virk\u0161tai ir adatos.<br \/>\nSveikatos apsaugos ministerija informavo ASP\u012e \u00a0apie galim\u0105 \u0161e\u0161tosios doz\u0117s naudojim\u0105. Pristatant antr\u0105j\u0105 vakcinos siunt\u0105 \u012f sveikatos prie\u017ei\u016bros \u012fstaigas kartu buvo i\u0161si\u0173sti reikalavimus atitinkantys \u0161virk\u0161tai, adatos ir kitos skiepijimui reikalingos priemon\u0117s. Tod\u0117l vakcinacij\u0105 \u0161e\u0161t\u0105ja doze gydymo \u012fstaigos gali prad\u0117ti nedelsiant.<\/p>\n<p>Remiantis EVA rekomendacijomis, norint i\u0161 vieno flakono i\u0161traukti \u0161e\u0161ias dozes, reikia naudoti ma\u017eo neveikos t\u016brio \u0161virk\u0161tus ir (arba) adatas. Ma\u017eo neveikos t\u016brio \u0161virk\u0161to ir adatos derinio neveikos t\u016bris tur\u0117t\u0173 b\u016bti ne didesnis kaip 35 mikrolitrai. Jei naudojami standartiniai \u0161virk\u0161tai ir adatos, vakcinos gali nepakakti, kad i\u0161 flakono b\u016bt\u0173 i\u0161traukta \u0161e\u0161toji doz\u0117.<\/p>\n<p>Jei vakcinos kiekis, lik\u0119s flakone po penktosios doz\u0117s i\u0161traukimo, negali u\u017etikrinti visos doz\u0117s (0,3 ml), sveikatos prie\u017ei\u016bros specialistas turi i\u0161mesti flakon\u0105 ir jo turin\u012f. Vakcinos negalima pritraukti i\u0161 keli\u0173 flakon\u0173, kad b\u016bt\u0173 sudaryta visa doz\u0117.<\/p>\n<p><em>SAM Spaudos tarnyba<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Europos vaist\u0173 agent\u016bra (EVA) penktadien\u012f pritar\u0117 si\u016blymui d\u0117l \u0161e\u0161tos \u201eBioNTech\u201c ir \u201ePfizer\u201c vakcinos \u201eComirnaty\u201c doz\u0117s panaudojimo. Nuo \u0161iol Lietuvos asmens sveikatos prie\u017ei\u016bros \u012fstaigos (ASP\u012e), atsakingos u\u017e gyventoj\u0173 skiepijim\u0105 nuo COVID-19 ligos, gal\u0117s naudoti \u0161e\u0161t\u0105j\u0105 vakcinos doz\u0119. EVA penktadien\u012f rekomendavo Europos Komisijai papildyti Covid-19 vakcinos \u201eComirnaty\u201c charakteristik\u0173 santrauk\u0105, kad paruo\u0161toje vakcinoje gali b\u016bti 6 doz\u0117s. Nurodoma&hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[100],"tags":[],"class_list":["post-18065","post","type-post","status-publish","format-standard","hentry","category-del-covid-19","category-100","description-off"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7kWFe-4Hn","jetpack_featured_media_url":"","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/posts\/18065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/comments?post=18065"}],"version-history":[{"count":2,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/posts\/18065\/revisions"}],"predecessor-version":[{"id":18068,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/posts\/18065\/revisions\/18068"}],"wp:attachment":[{"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/media?parent=18065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/categories?post=18065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/tags?post=18065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}